Income investors probably don't need to worry about a dividend cut from Pfizer in the new year.

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4. Analysts expect the health care company to report quarterly earnings at 64 cents ...